IDYA PE Ratio & Valuation,Is IDYA Overvalued

IDYA Relative Valuation

IDYA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IDYA is overvalued; if below, it's undervalued.

Historical Valuation

IDEAYA Biosciences Inc (IDYA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -11.53. The fair price of IDEAYA Biosciences Inc (IDYA) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：33.37

Fair

-8.90

-4.87

EV/EBITDA

IDEAYA Biosciences Inc. (IDYA) has a current EV/EBITDA of -4.87. The 5-year average EV/EBITDA is -6.40. The thresholds are as follows: Strongly Undervalued below -17.59, Undervalued between -17.59 and -12.00, Fairly Valued between -0.81 and -12.00, Overvalued between -0.81 and 4.79, and Strongly Overvalued above 4.79. The current Forward EV/EBITDA of -4.87 falls within the Historic Trend Line -Fairly Valued range.

-4.94

EV/EBIT

IDEAYA Biosciences Inc. (IDYA) has a current EV/EBIT of -4.94. The 5-year average EV/EBIT is -6.11. The thresholds are as follows: Strongly Undervalued below -13.60, Undervalued between -13.60 and -9.85, Fairly Valued between -2.36 and -9.85, Overvalued between -2.36 and 1.38, and Strongly Overvalued above 1.38. The current Forward EV/EBIT of -4.94 falls within the Historic Trend Line -Fairly Valued range.

124.90

IDEAYA Biosciences Inc. (IDYA) has a current PS of 124.90. The 5-year average PS is 88.49. The thresholds are as follows: Strongly Undervalued below -100.25, Undervalued between -100.25 and -5.88, Fairly Valued between 182.86 and -5.88, Overvalued between 182.86 and 277.24, and Strongly Overvalued above 277.24. The current Forward PS of 124.90 falls within the Historic Trend Line -Fairly Valued range.

-13.49

P/OCF

IDEAYA Biosciences Inc. (IDYA) has a current P/OCF of -13.49. The 5-year average P/OCF is -11.97. The thresholds are as follows: Strongly Undervalued below -40.16, Undervalued between -40.16 and -26.06, Fairly Valued between 2.12 and -26.06, Overvalued between 2.12 and 16.21, and Strongly Overvalued above 16.21. The current Forward P/OCF of -13.49 falls within the Historic Trend Line -Fairly Valued range.

-12.28

P/FCF

IDEAYA Biosciences Inc. (IDYA) has a current P/FCF of -12.28. The 5-year average P/FCF is -12.74. The thresholds are as follows: Strongly Undervalued below -33.69, Undervalued between -33.69 and -23.21, Fairly Valued between -2.26 and -23.21, Overvalued between -2.26 and 8.21, and Strongly Overvalued above 8.21. The current Forward P/FCF of -12.28 falls within the Historic Trend Line -Fairly Valued range.

IDEAYA Biosciences Inc (IDYA) has a current Price-to-Book (P/B) ratio of 2.68. Compared to its 3-year average P/B ratio of 2.72 , the current P/B ratio is approximately -1.36% higher. Relative to its 5-year average P/B ratio of 2.58, the current P/B ratio is about 3.68% higher. IDEAYA Biosciences Inc (IDYA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -8.24%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -6.40% , the current FCF yield is about -100.00% lower.

2.68

P/B

Median3y

2.72

Median5y

2.58

-3.53

FCF Yield

Median3y

-8.24

Median5y

-6.40

Competitors Valuation Multiple

The average P/S ratio for IDYA's competitors is , providing a benchmark for relative valuation. IDEAYA Biosciences Inc Corp (IDYA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of IDYA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of IDYA in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is IDEAYA Biosciences Inc (IDYA) currently overvalued or undervalued?

What is IDEAYA Biosciences Inc (IDYA) fair value?

IDYA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of IDEAYA Biosciences Inc (IDYA) is between NaN to NaN according to relative valuation methord.

How does IDYA's valuation metrics compare to the industry average?

What is the current P/B ratio for IDEAYA Biosciences Inc (IDYA) as of Dec 16 2025?

As of Dec 16 2025, IDEAYA Biosciences Inc (IDYA) has a P/B ratio of 2.68. This indicates that the market values IDYA at 2.68 times its book value.

What is the current FCF Yield for IDEAYA Biosciences Inc (IDYA) as of Dec 16 2025?

As of Dec 16 2025, IDEAYA Biosciences Inc (IDYA) has a FCF Yield of 0.00%. This means that for every dollar of IDEAYA Biosciences Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for IDEAYA Biosciences Inc (IDYA) as of Dec 16 2025?

As of Dec 16 2025, IDEAYA Biosciences Inc (IDYA) has a Forward P/E ratio of -8.90. This means the market is willing to pay $-8.90 for every dollar of IDEAYA Biosciences Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for IDEAYA Biosciences Inc (IDYA) as of Dec 16 2025?

As of Dec 16 2025, IDEAYA Biosciences Inc (IDYA) has a Forward P/S ratio of 0.00. This means the market is valuing IDYA at $0.00 for every dollar of expected revenue over the next 12 months.

IDYA Valuation